Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1127892

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what (a) health-and-safety research and (b) risk assessments his Department has (i) undertaken and (ii) commissioned on 5G technology.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256910
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>This explains the health-related reviews and assessments have been performed, as well as the practical measures that are in place to protect public health.</p><p>PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The guidelines apply to exposures at frequencies up to 300 GHz, well above the maximum few tens of GHz frequencies anticipated for use by 5G systems.</p><p>Health and safety legislation requires companies deploying and operating communication networks to carry out suitable and sufficient risk assessments, as well as put in place measures to reduce the identified risks so far as reasonably practicable. In controlling risks arising from radio wave exposure, the Health and Safety Executive refer to compliance with the ICNIRP guidelines. Industry has committed to comply with the international guidelines and to provide certificates of compliance with planning applications for base stations.</p><p>PHE continues to monitor the health-related evidence applicable to radio waves, including in relation to base stations, and is committed to updating its advice as required.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256911 256912 question first answered 29/05/2019 10:34:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127894

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether his Department has (a) undertaken and (b) commissioned a regulatory safety testing on 5G radiofrequency radiation.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256911
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>This explains the health-related reviews and assessments have been performed, as well as the practical measures that are in place to protect public health.</p><p>PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The guidelines apply to exposures at frequencies up to 300 GHz, well above the maximum few tens of GHz frequencies anticipated for use by 5G systems.</p><p>Health and safety legislation requires companies deploying and operating communication networks to carry out suitable and sufficient risk assessments, as well as put in place measures to reduce the identified risks so far as reasonably practicable. In controlling risks arising from radio wave exposure, the Health and Safety Executive refer to compliance with the ICNIRP guidelines. Industry has committed to comply with the international guidelines and to provide certificates of compliance with planning applications for base stations.</p><p>PHE continues to monitor the health-related evidence applicable to radio waves, including in relation to base stations, and is committed to updating its advice as required.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256910 256912 question first answered 29/05/2019 10:34:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127896

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	5G
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what plans he has to undertake (a) health-and-safety research and (b) a risk assessments before 5G is adopted in a localised test area.
tabling member constituency	Stroud
tabling member printed	Dr David Drew
uin	256912
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Public Health England (PHE) has published a webpage about exposure to the radio waves from mobile phone base stations, including those for 5G networks, at the following link:</p><p><a href="https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health" target="_blank">https://www.gov.uk/government/publications/mobile-phone-base-stations-radio-waves-and-health/mobile-phone-base-stations-radio-waves-and-health</a></p><p>This explains the health-related reviews and assessments have been performed, as well as the practical measures that are in place to protect public health.</p><p>PHE advises that the guidelines of the International Commission on Non-Ionizing Radiation Protection (ICNIRP) should be adopted and there is no convincing evidence that radio wave exposures below the ICNIRP guideline levels cause adverse health effects. The guidelines apply to exposures at frequencies up to 300 GHz, well above the maximum few tens of GHz frequencies anticipated for use by 5G systems.</p><p>Health and safety legislation requires companies deploying and operating communication networks to carry out suitable and sufficient risk assessments, as well as put in place measures to reduce the identified risks so far as reasonably practicable. In controlling risks arising from radio wave exposure, the Health and Safety Executive refer to compliance with the ICNIRP guidelines. Industry has committed to comply with the international guidelines and to provide certificates of compliance with planning applications for base stations.</p><p>PHE continues to monitor the health-related evidence applicable to radio waves, including in relation to base stations, and is committed to updating its advice as required.</p><p> </p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256910 256911 question first answered 29/05/2019 10:34:59 answering member 4455 label Biography information for Seema Kennedy
tabling member	252 label Biography information for Dr David Drew

1127908

registered interest
date	21/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Diabetes: Mental Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether an assessment has been made of the potential benefits of including a mental health professional with knowledge of diabetes in every diabetes care team.
tabling member constituency	Ealing Central and Acton
tabling member printed	Dr Rupa Huq
uin	257109
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>It is for individual clinical commissioning groups to commission treatment and services for people with diabetes and they are best placed to identify what is needed in their local areas.</p><p>On 21 March 2018, NHS England and NHS Improvement along with the National Collaborating Cenre for Mental Health published ‘The Improving Access to Psychological Therapies (IAPT) Pathway for People with Long-term Physical Health Conditions and Medically Unexplained Symptoms’.</p><p>IAPT services provide evidence based treatments for people with anxiety and depression and the services are co-located in existing primary and secondary care physical health pathways. IAPT services will target the needs of people with depression and anxiety disorders who also have long-term conditions such as diabetes.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 29/05/2019 13:39:35 answering member 4455 label Biography information for Seema Kennedy
tabling member	4511 label Biography information for Dr Rupa Huq

1127499

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Nusinersen
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what discussions his Department has held with (a) NICE, (b) NHS England and (c) Biogen on a Managed Access Agreement for SMA treatment Spinraza.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256254
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256255 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1127500

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	National Institute for Health and Care Excellence
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	256255
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256254 question first answered 29/05/2019 10:38:01 answering member 4455 label Biography information for Seema Kennedy
tabling member	1538 label Biography information for Rosie Cooper

1127581

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Cystic Fibrosis: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what the timetable is for the conclusion of negotiations between NHS England, NICE and Vertex on access to (a) Orkambi and (b) Symkevi for people with cystic fibrosis.
tabling member constituency	Birkenhead
tabling member printed	Frank Field
uin	256233
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>NHS England provided an update to the Health and Social Care Committee (HSCC) of the House of Commons on 23 May 2019, which can be found at the following link:</p><p><a href="https://www.parliament.uk/documents/commons-committees/Health/Correspondence/2017-19/19-05-23-NHS-England-update-availability-of-Orkambi-on-the-NHS.pdf" target="_blank">https://www.parliament.uk/documents/commons-committees/Health/Correspondence/2017-19/19-05-23-NHS-England-update-availability-of-Orkambi-on-the-NHS.pdf</a></p><p>This update informed the HSCC that a revised and improved offer had been made to Vertex Pharmaceuticals. Discussions between Vertex, NHS England and the National Institute for Health and Care Excellence (NICE) are ongoing.</p><p>The Government fully supports NICE and NHS England in seeking to ensure access for patients to effective and innovative medicines at a price that represents value to the National Health Service, and expects companies to engage realistically with NHS England and NICE regarding pricing issues. Where companies engage positively and show appropriate flexibility, it is possible to find a way to enable access to important treatments in a way that is also cost effective for the NHS.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 29/05/2019 11:10:57 answering member 4455 label Biography information for Seema Kennedy
tabling member	478 label Biography information for Lord Field of Birkenhead

1127588

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Health Centres: Skellingthorpe
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of the planned closure of Skellingthorpe Health Centre on local provision of health services.
tabling member constituency	Lincoln
tabling member printed	Karen Lee
uin	256372
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Lincolnshire Clinical Commissioning Group has received an application from the Glebe Practice regarding the proposed closure of its branch surgery in Skellingthorpe. It will be carrying out a public consultation and an equality impact assessment will be presented to the Primary Care Commissioning Committee prior to any decision being made.</p><p>When a general practitioner practice closes, patients are informed and advised to register at other local practices of their choice within the catchment area in which they live. In some instances, and in consultation with patients and patient groups, patients are allocated to other neighbouring practices with adequate capacity. Commissioners locally will work with their practices to ensure they are only allocated a volume of patients which they have capacity to manage appropriately and effectively.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 29/05/2019 10:54:24 answering member 4455 label Biography information for Seema Kennedy
tabling member	4664 label Biography information for Karen Lee

1127624

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Prescriptions: Fees and Charges
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, if he will undertake a review of the list of medical conditions for which patients are exempt from prescription charges to provide a list that is reflective of current health conditions.
tabling member constituency	Chesterfield
tabling member printed	Toby Perkins
uin	256296
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>The Department has no plans to review the current system of medical exemptions from prescription charges. Extensive arrangements are already in place to help people access National Health Service prescriptions. These include a broad range of NHS prescription charge exemptions.</p><p>To support those with the greatest need who do not qualify for an exemption, the cost of prescription pre-payment certificates has been frozen for another year. A holder of a 12-month certificate can get all the prescriptions they need for just £2 per week.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 29/05/2019 11:22:03 answering member 4455 label Biography information for Seema Kennedy
tabling member	3952 label Biography information for Mr Toby Perkins

1127652

registered interest
date	20/05/2019
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Analgesics: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to prevent people from becoming addicted to pain relief medication.
tabling member constituency	Strangford
tabling member printed	Jim Shannon
uin	256398
answer	answer is ministerial correction date of answer 29/05/2019 answer text <p>Painkillers including opioids are important to help people manage pain, but they must be treated with caution and the Government is taking action to protect people from addiction and inappropriate prescribing. Public Health England is reviewing problems associated with prescription medicine use, including opioids. In the interim we have introduced prominent addiction warnings for all opioid medicines and are making sure prevention and social prescribing are at the heart of our Long Term Plan to cut down on over-prescribing.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 256404 question first answered 29/05/2019 10:41:45 answering member 4455 label Biography information for Seema Kennedy
tabling member	4131 label Biography information for Jim Shannon